Azacitidine
- TRADE NAME: Vidaza (Celgene)
- INDICATIONS: Myelodysplastic syndromes, refractory anemia
- SYNONYM: Azacytidine
- CLASS: Antimetabolite, Antineoplastic / anticancer agent (see also Immune checkpoint inhibitor), Cytosine analog
- HALF-LIFE: 40–56 minutes
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
BCG Vaccine, Denosumab, Echinacea, Leflunomide, Natalizumab, Pimecrolimus, Sipuleucel-T, Tacrolimus, Trastuzumab, Vaccines
PREGNANCY CATEGORY: D
Contra-indicated in patients with advanced malignant hepatic tumors.
Please login to see the rest of this drug profile
SKIN.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
HEMATOLOGIC.
LOCAL.
NEUROMUSCULAR/SKELETAL.
OCULAR.
RENAL.
RESPIRATORY.
OTHER.
Page last updated 03/02/2024
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric